Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages 693-698

  Blann, Andrew D ^a   Banerjee, Amitava ^a   Lane, Deirdre A ^a   Torp Pedersen, Christian ^b   Lip, Gregory Y H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Atrial fibrillation; Bleeding; Edoxaban; Modelling; Net clinical benefit; Stroke

Indexed keywords

EDOXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; DRUG DOSE COMPARISON; EMBOLISM; HUMAN; NET CLINICAL BENEFIT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RISK; THROMBOEMBOLISM; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; EUROPE; FEMALE; HEALTH SURVEY; INCIDENCE; MALE; MULTICENTER STUDY; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; SURVIVAL RATE; THEORETICAL MODEL; TREATMENT OUTCOME; TRENDS;

ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FACTOR XA INHIBITORS; FEMALE; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; POPULATION SURVEILLANCE; PYRIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL RATE; THIAZOLES; TREATMENT OUTCOME;

EID: 84943515664     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.074     Document Type: Article

References (18)

1. A.J. Camm, G.Y.H. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, G. Hindricks, and P. Kirchhof 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2719 2747
2. D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, and A.S. Go The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann. Intern. Med. 151 2009 297 305
3. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation J. Am. Med. Assoc. 285 2001 2864 2870
4. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
5. C.S. Landefeld, and R.J. Beyth Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am. J. Med. 95 1993 315 328
6. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
7. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin, and RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
8. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, R.M. Califf, and ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
9. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin, and Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
10. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Špinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman, and ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
11. J.B. Olesen, G.Y. Lip, J. Lindhardsen, D.A. Lane, O. Ahlehoff, M.L. Hansen, J. Raunsø, J.S. Tolstrup, P.R. Hansen, G.H. Gislason, and C. Torp-Pedersen Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study Thromb. Haemost. 106 2011 739 749
12. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb. Haemost. 107 2012 584 589
13. J.B. Olesen, P.R. Hansen, S.Z. Abildstrøm, C. Andersson, P. Weeke, M. Schmiegelow, J. Erdal, C. Torp-Pedersen, and G.H. Gislason Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study Pharmacoepidemiol. Drug Saf. 20 2011 146 153
14. M.L. Hansen, R. Sørensen, M.T. Clausen, M.L. Fog-Petersen, J. Raunsø, N. Gadsbøll, G.H. Gislason, F. Folke, S.S. Andersen, T.K. Schramm, S.Z. Abildstrøm, H.E. Poulsen, L. Køber, and C. Torp-Pedersen Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch. Intern. Med. 170 2010 1433 1441
15. R. Sørensen, M.L. Hansen, S.Z. Abildstrom, A. Hvelplund, C. Andersson, C. Jørgensen, J.K. Madsen, P.R. Hansen, L. Køber, C. Torp-Pedersen, and G.H. Gislason Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
16. D. Caldeira, M. Barra, F.J. Pinto, J.J. Ferreira, and J. Costa Intracranial haemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis J. Neurol. 262 2015 516 522
17. P. Gallego, V. Roldan, F. Marin, J. Galvez, M. Valdes, V. Vicente, and G.Y.H. Lip SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am. J. Med. 127 2014 1083 1088
18. A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb. Haemost. 106 2011 968 977